Continue to Site

Drug Discovery and Development

Everest Organics begins manufacturing API for molnupiravir 

By |

Molnupiravir

Molnupiravir photo courtesy of Merck.

Bengaluru, India–based Everest Organics (BOM:524790) saw its share price jump 15% today to ₹347.10 after announcing it has begun manufacturing the active pharmaceutical ingredient (API) for a molnupiravir generic.

Molnupiravir is an experimental oral drug that appears to substantially reduce the rate of COVID-19-related hospitalization for patients with mild-to-moderate infections.

Reuters has reported that molnupiravir developer Merck (​​NYSE:MRK) has agreements with multiple Indian companies related to the manufacture of the drug.

Merck partnered with Ridgeback Biotherapeutics in developing molnupiravir, which scientists with ties to Emory University initially discovered.

“After the successful development and commercialization of various COVID-19 drugs, such as Oseltamivir, Remdesivir, [and] Posaconazole, Everest Organics Limited is on its path of expansion of this portfolio,” said Everest Organics CEO Srikakarlapudi Sirisha in a statement.

Everest notes that its Hyderabad facility exports APIs to drug companies in more than 40 countries.

Merck formally filed for emergency use authorization of the drug on Monday.

Filed Under: Drug Discovery, Infectious Disease
Tagged With: , , , , ,
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development